A Single-Arm, Open Phase II Clinical Trial of Anti-PD-1 Antibody SHR-1210 Plus Apatinib as Second-Line Treatment of Advanced Esophageal Squamous Cell
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2019
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 23 Jan 2019 Planned End Date changed from 1 Dec 2020 to 1 Feb 2021.
- 23 Jan 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Feb 2020.
- 23 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Feb 2019.